NCT00535665View on ClinicalTrials.gov

Safety and Immunogenicity of an Inactivated Pandemic Influenza Vaccine

PHASE2CompletedINTERVENTIONAL
Enrollment

402

Participants

Timeline

Start Date

September 30, 2007

Study Completion Date

November 30, 2007

Conditions
Pandemic InfluenzaPrevention
Interventions
BIOLOGICAL

pandemic influenza vaccine (H5N1 strain NIBRG-14)

two-dose regimen with 14 days apart: 5 microgram per dose

BIOLOGICAL

pandemic influenza vaccine (H5N1 strain NIBRG-14)

two-dose regimen with 28 days apart: 5 microgram per dose

BIOLOGICAL

pandemic influenza vaccine (H5N1 strain NIBRG-14)

two-dose regimen with 28 days apart: 10 microgram per dose

BIOLOGICAL

pandemic influenza vaccine (H5N1 strain NIBRG-14)

two-dose regimen with 28 days apart: 15 microgram per dose

All Listed Sponsors
collaborator

Centers for Disease Control and Prevention, China

OTHER_GOV

lead

Sinovac Biotech Co., Ltd

INDUSTRY

NCT00535665 - Safety and Immunogenicity of an Inactivated Pandemic Influenza Vaccine | Biotech Hunter | Biotech Hunter